DE60116137T2 - Derivatisierung von proteinen in wässrigem lösungsmittel - Google Patents

Derivatisierung von proteinen in wässrigem lösungsmittel Download PDF

Info

Publication number
DE60116137T2
DE60116137T2 DE60116137T DE60116137T DE60116137T2 DE 60116137 T2 DE60116137 T2 DE 60116137T2 DE 60116137 T DE60116137 T DE 60116137T DE 60116137 T DE60116137 T DE 60116137T DE 60116137 T2 DE60116137 T2 DE 60116137T2
Authority
DE
Germany
Prior art keywords
protein
derivatization
groups
acid
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60116137T
Other languages
German (de)
English (en)
Other versions
DE60116137D1 (de
Inventor
Gregory Gregoriadis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipoxen Technologies Ltd
Original Assignee
Lipoxen Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipoxen Technologies Ltd filed Critical Lipoxen Technologies Ltd
Application granted granted Critical
Publication of DE60116137D1 publication Critical patent/DE60116137D1/de
Publication of DE60116137T2 publication Critical patent/DE60116137T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01006—Catalase (1.11.1.6)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
DE60116137T 2000-05-16 2001-05-14 Derivatisierung von proteinen in wässrigem lösungsmittel Expired - Lifetime DE60116137T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00304108 2000-05-16
EP00304108 2000-05-16
PCT/GB2001/002115 WO2001087922A2 (en) 2000-05-16 2001-05-14 Derivatisation of proteins in aqueous solution

Publications (2)

Publication Number Publication Date
DE60116137D1 DE60116137D1 (de) 2006-01-26
DE60116137T2 true DE60116137T2 (de) 2006-08-24

Family

ID=8172993

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60116137T Expired - Lifetime DE60116137T2 (de) 2000-05-16 2001-05-14 Derivatisierung von proteinen in wässrigem lösungsmittel

Country Status (8)

Country Link
US (1) US6962972B2 (https=)
EP (1) EP1335931B1 (https=)
JP (1) JP2003533537A (https=)
AT (1) ATE313554T1 (https=)
AU (1) AU2001258536A1 (https=)
DE (1) DE60116137T2 (https=)
ES (1) ES2256234T3 (https=)
WO (1) WO2001087922A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007501888A (ja) * 2003-08-12 2007-02-01 リポクセン テクノロジーズ リミテッド ポリシアル酸誘導体
WO2005016974A1 (en) 2003-08-12 2005-02-24 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
US8652334B2 (en) * 2004-08-12 2014-02-18 Lipoxen Technologies Limited Fractionation of charged polysaccharide
WO2006016168A2 (en) * 2004-08-12 2006-02-16 Lipoxen Technologies Limited Sialic acid derivatives
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
CN101160326B (zh) 2005-02-23 2013-04-10 利普生技术有限公司 用于蛋白质衍生和缀合的活化的唾液酸衍生物
WO2008012528A1 (en) * 2006-07-25 2008-01-31 Lipoxen Technologies Limited N-terminal polysialylation
JP2010520320A (ja) 2007-02-28 2010-06-10 リポクセン テクノロジーズ リミテッド ポリシアル酸におけるエンドトキシンの低減
CN106110311A (zh) * 2009-07-27 2016-11-16 百深公司 凝血蛋白缀合物
KR101912335B1 (ko) 2009-07-27 2018-10-26 리폭센 테크놀로지즈 리미티드 비혈액 응고 단백질의 글리코폴리시알화
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
DK2598172T3 (da) 2010-07-30 2019-07-01 Baxalta GmbH Nukleofile katalysatorer til oximforbindelse
EP3808378A1 (en) 2011-05-27 2021-04-21 Baxalta GmbH Therapeutic proteins with increased half-life and methods of preparing same
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
DK2804623T3 (da) 2012-01-12 2019-11-11 Bioverativ Therapeutics Inc Kimære faktor viii-polypeptider og anvendelser deraf
BR112014020694A2 (pt) 2012-02-15 2018-05-08 Amunix Operating Inc. proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
JP2015525222A (ja) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． キメラ性凝固因子
EP2858659B1 (en) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Procoagulant compounds
HRP20200007T1 (hr) 2012-07-11 2020-03-20 Bioverativ Therapeutics Inc. Kompleks proteina faktora viii s xten i von willebrandovim faktorom, te njegova uporaba
SG10201710616XA (en) 2013-06-28 2018-02-27 Biogen Ma Inc Thrombin cleavable linker with xten and its uses thereof
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
WO2015048330A2 (en) 2013-09-25 2015-04-02 Biogen Idec Ma Inc. On-column viral inactivation methods
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
AU2015204646B2 (en) 2014-01-10 2020-08-27 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
WO2015130963A2 (en) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
US20180022780A1 (en) 2014-09-26 2018-01-25 Bayer Pharma Aktiengesellschaft Stabilization adrenomedullin derivatives and use thereof
ES2753391T3 (es) 2014-10-14 2020-04-08 Halozyme Inc Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
CA3007364A1 (en) 2015-12-03 2017-06-08 Baxalta Incorporated Factor viii with extended half-life and reduced ligand-binding properties
EA201892249A1 (ru) 2016-04-04 2019-05-31 Шайр Хьюман Дженетик Терапиз, Инк. Конъюгированный ингибитор c1-эстеразы и пути его применения
JP7464530B2 (ja) 2018-03-28 2024-04-09 ブリストル－マイヤーズ スクイブ カンパニー インターロイキン－２／インターロイキン－２受容体アルファ融合タンパク質および使用方法
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a
CA3104686A1 (en) 2018-07-03 2020-01-09 Bristol-Myers Squibb Company Fgf-21 formulations
CA3143584A1 (en) 2019-06-18 2020-12-24 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4727136A (en) 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US5846951A (en) * 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
GB9112212D0 (en) 1991-06-06 1991-07-24 Gregoriadis Gregory Pharmaceutical compositions
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process

Also Published As

Publication number Publication date
ES2256234T3 (es) 2006-07-16
EP1335931B1 (en) 2005-12-21
DE60116137D1 (de) 2006-01-26
US20030129159A1 (en) 2003-07-10
AU2001258536A1 (en) 2001-11-26
JP2003533537A (ja) 2003-11-11
WO2001087922A2 (en) 2001-11-22
ATE313554T1 (de) 2006-01-15
WO2001087922A3 (en) 2003-05-30
US6962972B2 (en) 2005-11-08
EP1335931A2 (en) 2003-08-20

Similar Documents

Publication Publication Date Title
DE60116137T2 (de) Derivatisierung von proteinen in wässrigem lösungsmittel
DE69533987T2 (de) Protein oder polypeptid, verfahren zur seiner herstellung und entsprechende zwischenprodukte
DE69634373T2 (de) Verfahren zur Herstellung von Konjugaten vom Faktor VIII mit einem biologisch verträglichen Polymer
EP0265865B1 (de) Blutersatzmittel
EP0912197B1 (de) Hämoglobin-hydroxyethylstärke-konjugate als sauerstoff-transport-mittel
EP0253303B1 (de) Neue Metallchelatharze
DE69917889T2 (de) Polyethylenglycolderivate mit benachbarten reaktiven gruppen
DE69231935T2 (de) Konjugat enthaltend ein geradkettiges organisches polymer mit gebundenen sulfatierten glukosaminoglukanen wie zum beispiel heparin, seine herstellung, verwendung und ein entsprechendes substrat
DE2906504C2 (de) Glycoproteinderivat-Zubereitungen, Verfahren zu ihrer Herstellung und ihre Verwendung als diagnostische Reagentien oder hydrolytische Katalysatoren
EP0078961B1 (de) Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat
DE3102621C2 (https=)
DE69020276T2 (de) Amylose-Lysozym-Hybrid, ein Aktivzucker und Verfahren zur Herstellung.
DE68901944T2 (de) Makromolekulare haemoglobinkomplexe, verfahren zu ihrer herstellung und ihre verwendungen.
DE2449885B2 (de) Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat
DE10112825A1 (de) HESylierung von Wirkstoffen in wässriger Lösung
EP1294385B1 (de) Verfahren zur herstellung künstlicher sauerstoffträger aus kovalent vernetzten hämoglobinen mit verbesserten funktionellen eigenschaften durch vernetzung in anwesenheit chemisch nicht reagierender effektoren der sauerstoffaffinität der hämoglobine
DE3876997T2 (de) Konjugate von superoxiddismutase.
DE3026398A1 (de) Modifiziertes haemoglobin enthaltender blutersatz
EP1476470B1 (de) ST RKEDERIVATE, ST RKE−WIRKSTOFF−KONJ UGATE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG ALS ARZNEIMITTEL
DE2240782A1 (de) Verfahren zur herstellung eines eisensaccharid-komplexes
DE2423831A1 (de) Verfahren zur aktivierung von kohlehydraten fuer die umsetzung mit proteinen
DE2430356A1 (de) Verfahren zur markierung von immunoglobulin oder dessen fc-fragment und mittel zur durchfuehrung des verfahrens
DE3786832T2 (de) Verfahren zur Herstellung von Immunoglobulinzubereitungen für intravenöse Injektion.
DE2433883A1 (de) Geschuetztes polypeptid, im wesentlichen nicht immunogene, enzymisch aktive substanz sowie verfahren zum weitgehenden unterdruekken der immunogenizitaet eines polypeptids
DE69030553T2 (de) Verfahren zur Herstellung modifizierter Superoxid-Dismutase

Legal Events

Date Code Title Description
8364 No opposition during term of opposition